Literature DB >> 22387555

Increased Th17 and regulatory T cell responses in EBV-induced gene 3-deficient mice lead to marginally enhanced development of autoimmune encephalomyelitis.

Jin-Qing Liu1, Zhenzhen Liu, Xuejun Zhang, Yun Shi, Fatemeh Talebian, Joseph W Carl, Chuan Yu, Fu-Dong Shi, Caroline C Whitacre, Joanne Trgovcich, Xue-Feng Bai.   

Abstract

EBV-induced gene 3 (EBI3)-encoded protein can form heterodimers with IL-27P28 and IL-12P35 to form IL-27 and IL-35. IL-27 and IL-35 may influence autoimmunity by inhibiting Th17 differentiation and facilitating the inhibitory roles of Foxp3(+) regulatory T (Treg) cells, respectively. In this study, we have evaluated the development of experimental autoimmune encephalomyelitis (EAE) in EBI3-deficient mice that lack both IL-27 and IL-35. We found that myelin oligodendrocyte glycoprotein peptide immunization resulted in marginally enhanced EAE development in EBI3-deficient C57BL6 and 2D2 TCR-transgenic mice. EBI3 deficiency resulted in significantly increased Th17 and Th1 responses in the CNS and increased T cell production of IL-2 and IL-17 in the peripheral lymphoid organs. EBI3-deficient and -sufficient 2D2 T cells had equal ability in inducing EAE in Rag1(-/-) mice; however, more severe disease was induced in EBI3(-/-)Rag1(-/-) mice than in Rag1(-/-) mice by 2D2 T cells. EBI3-deficient mice had increased numbers of CD4(+)Foxp3(+) Treg cells in peripheral lymphoid organs. More strikingly, EBI3-deficient Treg cells had more potent suppressive functions in vitro and in vivo. Thus, our data support an inhibitory role for EBI3 in Th17, Th1, IL-2, and Treg responses. Although these observations are consistent with the known functions of IL-27, the IL-35 contribution to the suppressive functions of Treg cells is not evident in this model. Increased Treg responses in EBI3(-/-) mice may explain why the EAE development is only modestly enhanced compared with wild-type mice.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22387555      PMCID: PMC3311737          DOI: 10.4049/jimmunol.1100106

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  36 in total

1.  Cutting edge: role of IL-27/WSX-1 signaling for induction of T-bet through activation of STAT1 during initial Th1 commitment.

Authors:  Atsunobu Takeda; Shinjiro Hamano; Atsushi Yamanaka; Toshikatsu Hanada; Tatsuro Ishibashi; Tak W Mak; Akihiko Yoshimura; Hiroki Yoshida
Journal:  J Immunol       Date:  2003-05-15       Impact factor: 5.422

2.  WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27.

Authors:  Stefan Pflanz; Linda Hibbert; Jeanine Mattson; Rency Rosales; Elena Vaisberg; J Fernando Bazan; Joseph H Phillips; Terrill K McClanahan; Rene de Waal Malefyt; Robert A Kastelein
Journal:  J Immunol       Date:  2004-02-15       Impact factor: 5.422

3.  Disruption of T helper 2-immune responses in Epstein-Barr virus-induced gene 3-deficient mice.

Authors:  Edward E S Nieuwenhuis; Markus F Neurath; Nadia Corazza; Hideki Iijima; Joanne Trgovcich; Stefan Wirtz; Jonathan Glickman; Dan Bailey; Masaru Yoshida; Peter R Galle; Mitchell Kronenberg; Mark Birkenbach; Richard S Blumberg
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-13       Impact factor: 11.205

4.  Development of Th1-type immune responses requires the type I cytokine receptor TCCR.

Authors:  Q Chen; N Ghilardi; H Wang; T Baker; M H Xie; A Gurney; I S Grewal; F J de Sauvage
Journal:  Nature       Date:  2000-10-19       Impact factor: 49.962

5.  A role for IL-27 in limiting T regulatory cell populations.

Authors:  Elia D Tait Wojno; Nancy Hosken; Jason S Stumhofer; Aisling C O'Hara; Elizabeth Mauldin; Qun Fang; Laurence A Turka; Steven D Levin; Christopher A Hunter
Journal:  J Immunol       Date:  2011-05-27       Impact factor: 5.422

6.  IL-27 regulates IL-12 responsiveness of naive CD4+ T cells through Stat1-dependent and -independent mechanisms.

Authors:  Sophie Lucas; Nico Ghilardi; Ji Li; Frédéric J de Sauvage
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-01       Impact factor: 11.205

7.  Hyperproduction of proinflammatory cytokines by WSX-1-deficient NKT cells in concanavalin A-induced hepatitis.

Authors:  Atsushi Yamanaka; Shinjiro Hamano; Yoshiyuki Miyazaki; Kazunari Ishii; Atsunobu Takeda; Tak W Mak; Kunisuke Himeno; Akihiko Yoshimura; Hiroki Yoshida
Journal:  J Immunol       Date:  2004-03-15       Impact factor: 5.422

8.  The IL-27R (WSX-1) is required to suppress T cell hyperactivity during infection.

Authors:  Alejandro Villarino; Linda Hibbert; Linda Lieberman; Emma Wilson; Tak Mak; Hiroki Yoshida; Robert A Kastelein; Christiaan Saris; Christopher A Hunter
Journal:  Immunity       Date:  2003-11       Impact factor: 31.745

9.  CD24 controls expansion and persistence of autoreactive T cells in the central nervous system during experimental autoimmune encephalomyelitis.

Authors:  Xue-Feng Bai; Ou Li; Qunmin Zhou; Huiming Zhang; Pramod S Joshi; Xincheng Zheng; Yan Liu; Yin Wang; Pan Zheng; Yang Liu
Journal:  J Exp Med       Date:  2004-08-16       Impact factor: 14.307

10.  Myelin oligodendrocyte glycoprotein-specific T cell receptor transgenic mice develop spontaneous autoimmune optic neuritis.

Authors:  Estelle Bettelli; Maria Pagany; Howard L Weiner; Christopher Linington; Raymond A Sobel; Vijay K Kuchroo
Journal:  J Exp Med       Date:  2003-05-05       Impact factor: 14.307

View more
  42 in total

1.  Remission of systemic lupus erythematosus disease activity with regulatory cytokine interleukin (IL)-35 in Murphy Roths Large (MRL)/lpr mice.

Authors:  Z Cai; C K Wong; J Dong; M Chu; D Jiao; N W Kam; C W K Lam; L S Tam
Journal:  Clin Exp Immunol       Date:  2015-08       Impact factor: 4.330

Review 2.  Interleukin-35: Expanding Its Job Profile.

Authors:  Deepali V Sawant; Kristia Hamilton; Dario A A Vignali
Journal:  J Interferon Cytokine Res       Date:  2015-04-28       Impact factor: 2.607

Review 3.  IL-35 and Autoimmunity: a Comprehensive Perspective.

Authors:  Jinjung Choi; Patrick S C Leung; Christopher Bowlus; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2015-12       Impact factor: 8.667

Review 4.  Induced and natural regulatory T cells in the development of inflammatory bowel disease.

Authors:  Christopher G Mayne; Calvin B Williams
Journal:  Inflamm Bowel Dis       Date:  2013-07       Impact factor: 5.325

5.  Oral Escherichia coli colonization factor antigen I fimbriae ameliorate arthritis via IL-35, not IL-27.

Authors:  Irina Kochetkova; Theresa Thornburg; Gayle Callis; Kathryn Holderness; Massimo Maddaloni; David W Pascual
Journal:  J Immunol       Date:  2013-12-11       Impact factor: 5.422

6.  Epstein-Barr virus-induced gene 3-deficiency leads to impaired antitumor T-cell responses and accelerated tumor growth.

Authors:  Zhenzhen Liu; Jin-Qing Liu; Yun Shi; Xiaotong Zhu; Zhihao Liu; Ming-Song Li; Jianhua Yu; Lai-Chu Wu; Yukai He; Guoqiang Zhang; Xue-Feng Bai
Journal:  Oncoimmunology       Date:  2015-01-09       Impact factor: 8.110

7.  Epstein-Barr virus-induced gene 3 (EBI3) can mediate IL-6 trans-signaling.

Authors:  Salma Chehboun; Jérémie Labrecque-Carbonneau; Sarah Pasquin; Yasmine Meliani; Bouchra Meddah; Walter Ferlin; Mukut Sharma; Aurélie Tormo; Jean-François Masson; Jean-François Gauchat
Journal:  J Biol Chem       Date:  2017-03-09       Impact factor: 5.157

8.  IL-35 may maintain homeostasis of the immune microenvironment in periodontitis.

Authors:  Ying Jin; Dixin Liu; Xiaoping Lin
Journal:  Exp Ther Med       Date:  2017-10-03       Impact factor: 2.447

9.  Gene Expression and Antiviral Activity of Interleukin-35 in Response to Influenza A Virus Infection.

Authors:  Li Wang; Shengli Zhu; Gang Xu; Jian Feng; Tao Han; Fanpeng Zhao; Ying-Long She; Shi Liu; Linbai Ye; Ying Zhu
Journal:  J Biol Chem       Date:  2016-06-15       Impact factor: 5.157

10.  IL-27 enhances the survival of tumor antigen-specific CD8+ T cells and programs them into IL-10-producing, memory precursor-like effector cells.

Authors:  Zhenzhen Liu; Jin-Qing Liu; Fatemeh Talebian; Lai-Chu Wu; Shulin Li; Xue-Feng Bai
Journal:  Eur J Immunol       Date:  2013-01-15       Impact factor: 5.532

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.